BioCardia (BCDA) AI Stock Analysis

• Market Cap: $9.96M
• Dividend Yield: N/A
• Average Volume (3M): 556.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.21
• Revenue Growth: -99.36%
• EPS Growth: 63.06%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 5,503,802
• 10 Day Avg. Volume: 1,179,426
• 30 Day Avg. Volume: 556,792
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: -212.29
• Enterprise Value/Gross Profit: -54.82
• Enterprise Value/Ebitda: -2.06
• 1Y Price Target: $6.00
• Price Target Upside: 231.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $2.00 ▲(10.50% Upside)

BioCardia's overall stock score is primarily constrained by its challenging financial performance and unattractive valuation. The stock's technical indicators suggest bearish momentum. However, recent clinical advancements and corporate events provide a potential for future growth, which slightly offsets the negative aspects.

Positive Factors

Financial Performance

Biocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.

Financial Stability

The company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.

New Product

Morph DNA Introducer now commercially available, providing new revenue stream.

Negative Factors

Clinical Trial

DSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.

Regulatory Challenges

PMDA willing to review CardiAMP HF data ahead of submission for approval in Japan.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

How the Company Makes Money

BioCardia generates revenue through a combination of product sales, licensing agreements, and collaborations. The company primarily aims to commercialize its cell therapy candidates, such as CardiAMP and CardiALLO, upon successful completion of clinical trials and regulatory approvals. BioCardia also earns revenue from licensing its proprietary biotherapeutic delivery platform to other companies in the biopharmaceutical sector. Additionally, the company engages in partnerships and collaborations that provide research funding and milestone-based payments, further contributing to its revenue streams. These partnerships often align with BioCardia's strategic goals in advancing regenerative medicine solutions for cardiovascular diseases.

BioCardia Financial Statement Overview

Summary

BioCardia's financial performance is challenging, marked by negative income margins and reliance on financing. While there is a slight improvement in cash reserves and equity figures, the company's financial health remains weak due to high volatility and ongoing losses.

Income Statement

BioCardia's income statement indicates significant challenges with profitability, as evidenced by consistently negative EBIT and net income margins. Revenue has been highly volatile, with a dramatic decrease over the years and a substantial dip in gross profit. This volatility, coupled with negative margins, suggests financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet reveals a weak equity position with negative stockholders' equity in previous years, which has slightly improved to a positive figure recently. The debt-to-equity ratio is relatively high, indicating potential leverage risks. Despite an increase in cash and short-term investments, overall asset growth has been stagnant, raising concerns about long-term financial health.

Cash Flow

The cash flow statement shows consistently negative free cash flow, although there has been some improvement in operating cash flow relative to net income. High reliance on financing activities to manage cash flow needs highlights challenges in generating sufficient operating cash. This reliance on external financing can be risky if not managed carefully.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.00K	477.00K	1.35M	1.01M	145.00K
Gross Profit	-4.33M	-7.25M	-10.55M	375.00K	141.00K
EBITDA	-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
Net Income	-7.95M	-11.57M	-11.91M	-12.62M	-15.00M
Balance Sheet
Total Assets	3.72M	2.99M	9.79M	15.72M	23.42M
Cash, Cash Equivalents and Short-Term Investments	2.37M	1.10M	7.36M	12.87M	21.41M
Total Debt	951.00K	1.31M	1.63M	1.87M	614.00K
Total Liabilities	2.89M	4.59M	4.90M	5.34M	4.25M
Stockholders Equity	837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow
Free Cash Flow	-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
Operating Cash Flow	-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
Investing Cash Flow	-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
Financing Cash Flow	9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Negative. The current price of 1.81 is below the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.19, and below the 200-day MA of 2.29, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 30.30 is Neutral, neither overbought nor oversold. The STOCH value of 21.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	$10.74M	―	-83.92%	―	-67.87%	0.40%
Sector *	51 Neutral	$7.39B	0.42	-62.86%	2.37%	15.61%	-1.93%
PRTG	48 Neutral	$16.00M	―	-194.84%	―	―	48.91%
BRTX	48 Neutral	$11.18M	―	-117.16%	―	175.03%	55.34%
BCDA	45 Neutral	$9.96M	―	-737.89%	―	-99.36%	63.06%
ATNF	―	$26.62M	―	-371.02%	―	―	―
LYRA	46 Neutral	$10.79M	―	-195.46%	―	-29.46%	2.71%

BioCardia Corporate Events

BioCardia Updates Regulatory Timeline for Helix System

On August 4, 2025, BioCardia, Inc. announced updates on the regulatory approval timeline for its CardiAMP® Cell Therapy System and Helix Transendocardial Delivery Catheter. The company plans to submit a DeNovo 510(k) application for the Helix system to the FDA in Q3 2025, leveraging its safety and performance in numerous clinical studies. Additionally, BioCardia aims to discuss the approval pathway for CardiAMP Cell Therapy for ischemic heart failure with the FDA in Q4 2025, highlighting its previous Breakthrough Designation and clinical trial results. A clinical consultation with Japan’s PMDA is also expected in Q4 2025, potentially facilitating market entry in Japan. These developments could significantly impact BioCardia’s market positioning and provide new opportunities for stakeholders.

The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Submits CardiAMP Therapy for PMDA Review

On July 24, 2025, BioCardia announced the submission of its CardiAMP autologous cell therapy for heart failure to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for clinical consultation. This submission is a crucial step towards potential regulatory approval in Japan, a significant market for advanced heart failure treatments. The consultation will involve a comprehensive review of clinical data from the CardiAMP HF trial, assessing the therapy’s efficacy, safety, and fit within the Japanese healthcare system. Successful alignment with PMDA could lead to market entry in Japan and a subsequent post-marketing study, enhancing BioCardia’s industry positioning and offering new opportunities for collaboration.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Launches Phase 3 CardiAMP HF II Trial

On July 16, 2025, BioCardia announced that Henry Ford Health in Detroit, Michigan, has begun enrolling patients with ischemic heart failure in the company’s pivotal Phase 3 CardiAMP HF II trial. This trial is a confirmatory study of autologous bone marrow-derived mononuclear cell therapy, aiming to promote microvascular repair and improve heart function in patients with ischemic heart failure. The trial seeks to confirm the safety and efficacy results observed in previous studies and could potentially enhance treatment options for patients with heart failure.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Completes Private Placement Agreement

On June 30, 2025, BioCardia, Inc. completed a private placement agreement with institutional buyers and company insiders, raising approximately $570,000. The funds will be used for general corporate purposes, and the company plans to register the shares for resale with the SEC by July 10, 2025.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Secures Patent for Innovative Catheter System

On June 25, 2025, BioCardia announced the granting of US Patent No. 12,311,127 for its ‘Radial and Trans-endocardial Delivery Catheter’ by the United States Patent Office. This patent covers BioCardia’s minimally invasive catheter systems designed to deliver biologic therapies to the heart, enhancing treatment precision and safety. The Helix catheter system, integral to the company’s CardiAMP Cell Therapy program, is expected to significantly impact the treatment of ischemic cardiomyopathies and heart failure, potentially improving patient outcomes and facilitating the transition from development to commercialization.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Advances Phase 3 CardiAMP HF II Trial

On May 6, 2025, BioCardia, Inc. announced that the University of Wisconsin in Madison has begun enrolling patients with ischemic heart failure in the ongoing pivotal Phase 3 CardiAMP HF II trial. This study is evaluating the CardiAMP cell therapy product for treating patients with ischemic heart failure with reduced ejection fraction and elevated cardiac stress markers. The trial aims to confirm the safety and efficacy of the therapy, which has shown promising results in improving survival and quality of life for heart failure patients. The study’s advancements include refined treatment dose definitions and improvements to the Helix system, potentially expanding patient eligibility and treatment effectiveness.